Athersys company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

athersys.com

Founded Year

1995

Stage

Corporate Minority | Alive

Total Raised

$100.41M

Valuation

$0000 

Last Raised

$7.04M | 2 yrs ago

Revenue

$0000 

About Athersys

Athersys develops biotechnology-based therapeutics.

Athersys Headquarter Location

3201 Carnegie Avenue

Cleveland, Ohio, 44115,

United States

216-431-9900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Athersys

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Athersys is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Athersys Patents

Athersys has filed 17 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/6/2017

12/14/2021

Immunology, Immune system, Stem cells, Autoimmune diseases, Clusters of differentiation

Grant

Application Date

11/6/2017

Grant Date

12/14/2021

Title

Related Topics

Immunology, Immune system, Stem cells, Autoimmune diseases, Clusters of differentiation

Status

Grant

Latest Athersys News

Athersys to Participate in the H.C. Wainwright Global Investment Conference

May 13, 2022

May 13, 2022 08:00 AM Eastern Daylight Time CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. The Company’s management team will also participate in one-on-one meetings with institutional investors during the conference. Investors interested in arranging a meeting with the Company’s management during the conference should contact meetings@hcwo.com or dwilliamson@hcwo.com . The Company’s presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. This event can be accessed by visiting ‘ Events & Presentations ’ in the Investors Section on the Company's website. An archived replay of the webcast will be available on the Company's website after the conference for a limited time. About Athersys Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys . Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. Contacts

Athersys Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Athersys Rank

  • When was Athersys founded?

    Athersys was founded in 1995.

  • Where is Athersys's headquarters?

    Athersys's headquarters is located at 3201 Carnegie Avenue, Cleveland.

  • What is Athersys's latest funding round?

    Athersys's latest funding round is Corporate Minority.

  • How much did Athersys raise?

    Athersys raised a total of $100.41M.

  • Who are the investors of Athersys?

    Investors of Athersys include Healios K.K., BTHC VI, Pappas Ventures, Accipiter Capital Management, OrbiMed Advisors and 34 more.

  • Who are Athersys's competitors?

    Competitors of Athersys include Elusys Therapeutics, Amniotics, GangaGen, Seattle Genetics, Innate Pharma and 12 more.

You May Also Like

A
Alice Therapeutics

Alice Therapeutics is a biotechnology company.

H
Halsa Pharmaceuticals

Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.

K
Kemia

Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.

Pulmotect Logo
Pulmotect

Pulmotect is a biopharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

C
Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.